Ensign Peak Advisors’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.1M | Sell |
268,217
-6,050
| -2% | -$295K | 0.02% | 408 |
|
|
2025
Q1 | $14M | Buy |
274,267
+65,965
| +32% | +$3.36M | 0.03% | 380 |
|
|
2024
Q4 | $9.4M | Hold |
208,302
| – | – | 0.02% | 496 |
|
|
2024
Q3 | $7.73M | Hold |
208,302
| – | – | 0.01% | 522 |
|
|
2024
Q2 | $6.37M | Buy |
208,302
+180,561
| +651% | +$5.52M | 0.01% | 563 |
|
|
2024
Q1 | $807K | Sell |
27,741
-1,399
| -5% | -$40.7K | ﹤0.01% | 1457 |
|
|
2023
Q4 | $803K | Hold |
29,140
| – | – | ﹤0.01% | 1503 |
|
|
2023
Q3 | $653K | Hold |
29,140
| – | – | ﹤0.01% | 1484 |
|
|
2023
Q2 | $1.19M | Hold |
29,140
| – | – | ﹤0.01% | 1126 |
|
|
2023
Q1 | $1.41M | Sell |
29,140
-157,110
| -84% | -$7.61M | ﹤0.01% | 985 |
|
|
2022
Q4 | $7.11M | Buy |
186,250
+169,010
| +980% | +$6.45M | 0.02% | 481 |
|
|
2022
Q3 | $865K | Buy |
17,240
+1,450
| +9% | +$72.8K | ﹤0.01% | 1150 |
|
|
2022
Q2 | $633K | Buy |
15,790
+4,270
| +37% | +$171K | ﹤0.01% | 1340 |
|
|
2022
Q1 | $430K | Buy |
11,520
+1,520
| +15% | +$56.7K | ﹤0.01% | 1611 |
|
|
2021
Q4 | $398K | Buy |
10,000
+3,474
| +53% | +$138K | ﹤0.01% | 1709 |
|
|
2021
Q3 | $243K | Sell |
6,526
-12,042
| -65% | -$448K | ﹤0.01% | 1728 |
|
|
2021
Q2 | $785K | Hold |
18,568
| – | – | ﹤0.01% | 1496 |
|
|
2021
Q1 | $879K | Sell |
18,568
-36,757
| -66% | -$1.74M | ﹤0.01% | 1462 |
|
|
2020
Q4 | $3.38M | Buy |
55,325
+26,175
| +90% | +$1.6M | 0.01% | 776 |
|
|
2020
Q3 | $1.36M | Buy |
29,150
+22,576
| +343% | +$1.06M | ﹤0.01% | 1172 |
|
|
2020
Q2 | $334K | Hold |
6,574
| – | – | ﹤0.01% | 1525 |
|
|
2020
Q1 | $293K | Sell |
6,574
-10,224
| -61% | -$456K | ﹤0.01% | 1486 |
|
|
2019
Q4 | $806K | Buy |
+16,798
| New | +$806K | ﹤0.01% | 1405 |
|